logo

Aggressive Leukemia Assignment Report

   

Added on  2022-09-09

33 Pages7874 Words59 Views
 | 
 | 
 | 
Running head: MEDICAL
BIOMEDICAL SCIENCE
Name of the Student
Name of the University
Author Note
Aggressive Leukemia Assignment Report_1

Running head: MEDICAL1
Abstract
Aggressive leukemia (AML) has occurred with the incidence of one lakh cases and has been
observed to increase with age. The identification of genetic and molecular groups have been
increasingly studied for the treatment of AML. This disease has been characterized by
various chromosomal translocations and mutations associated with the gene differentiations
as FLT3, NPM1, CEBPA ASXL. Autophagy is the sequential process involving cell death
regulation and damaged cellular debris recycling is initiated by external and cellular cures to
maintain proper homeostasis and metabolism. This process is important for the regulation of
double-stranded DNA repair.
Table of Content
Aggressive Leukemia Assignment Report_2

Running head: MEDICAL2
s
Introduction................................................................................................................................4
AML (Acute Myeloid Leukaemia):.......................................................................................4
Treatment strategies:..............................................................................................................4
STAG2- Cohesin Complex:...................................................................................................5
DNA repair:............................................................................................................................5
Autophagy:.............................................................................................................................6
Chloroquine............................................................................................................................6
Rapamycin..............................................................................................................................6
Aims and Objectives..................................................................................................................7
Materials and Methods...............................................................................................................7
Reagents.................................................................................................................................7
Cell culturing and lines..........................................................................................................8
Cell subculture.......................................................................................................................8
Counting of cells....................................................................................................................8
Calculation of cell counting...................................................................................................9
Preparation of drug and addiction of drugs..........................................................................10
Alamar Blue Assay (Cell Viability).....................................................................................13
Cisplatin (Alkylating agent) - Combined drug therapy........................................................13
Statistical Analysis...............................................................................................................14
Results......................................................................................................................................14
Counting of cells:.................................................................................................................14
Aggressive Leukemia Assignment Report_3

Running head: MEDICAL3
Alamar Blue Assay: Cell Viability......................................................................................19
Discussion................................................................................................................................24
Conclusion................................................................................................................................29
References................................................................................................................................30
Aggressive Leukemia Assignment Report_4

Running head: MEDICAL4
Introduction
AML (Acute Myeloid Leukaemia):
According to various research studies, AML is a part of leukemia that occurs in
adults. The majority of the leukemia cases occurring in adults consists of AML as the root
cause (Li et al. 2019). This form of leukemia has been characterized by mutation
(translocation) in the gene differentiation and hematopoietic proliferation. This condition
farther leads to the accumulation of cells in the peripheral blood and bone marrow due to the
absence of an apoptotic mechanism. Thus, it is an important decision to choose an
appropriate method for the experiment. One of the best future methods for the conduction of
this experiment is the ((3-(4,5-dimethylthiazol-2-yl)-2–5-diphenyltetrazolium bromide) assay
(MTT) which is a colorimetric assay used for the access to cell viability and cellular toxicity
(Darwish et al. 2016). This procedure includes the use of succinate which is used to
determine the cellular viability. While MTT was added to the cells, NADH will work by
reducing it to a purple formazan that can be quantified by the use of light absorbance.
According to the statistical records, 12 people per 100,000 people over 65 years have more
chance of the disease than 1 individual per 100,000 people under 65 years (Saultz and Garzon
2016). This disease is diagnosed with a prevalence percentage of over 20% blast in peripheral
blood or bone marrow followed by the detection of myeloid progenitor cells in
myeloperoxidase test.
Treatment strategies:
Intensive induction chemotherapy with anthracycline administration for three days
and cytarabine for seven days allows a CR (complete remission) among 80% of the younger
adults. The percentage is 60% for older adults due to the reduced strength of their immune
system. Isocitrate inhibitors (IDH), FLT3 (Fms-like tyrosine kinase 3) and nuclear-exported
Aggressive Leukemia Assignment Report_5

Running head: MEDICAL5
inhibitors are some novel therapies devised for the treatment for this disease. Repair of
defective DNA, stabilization of genomic instability and deregulation of transcription are also
the major processes of AML treatment. Thus it can be understood that the treatment can be
induced from the DNA level (Dombret and Gardin 2016). Thus, this research study uses
mutation of STAG2 along with abnormal replication of DNA to induce lethality after using
cisplatin and chloroquine. These two drugs have been observed to modulate autophagy to
involve the replication of DNA. AML treatment options have minimal side effects and are
also associated with higher efficacy.
STAG2- Cohesin Complex:
The gene stag2 encodes the cohesion complex component that participates in the
sister chromatid regulation of separation required during mitosis. After the activation of
stag2, protein acts as a tumour suppressor disrupting the separation of mitotic sister
chromatin. According to various research studies it can be stated that the chromosomal
deletions involving Xq25 as observed in myelodysplasia and AML along with several
mutations in STAG2 hotspots regions known as exon 9,11,12,20 were identified as acute
leukaemia causes (Nishiyama 2019). STAG2 has also been observed to participate in the
inactivation of RUNX1, NPM1, and RB1 or CDKN2A/B (tumour suppressor genes). This
process is named as leukemogenesis.
DNA repair:
The genomic DNA gets damaged due to various factors including radiation,
environmental chemicals, UV light, and other external factors. These factors result in the
generation of reactive oxygen species (ROS) which gives rise to replication errors. Induction
of DSB (double-stranded breaks) occurs by an improper activation of Chk2 and the absence
of Rad21 leading to an increased probability of chromosomal rearrangement (Zatopek et al.
Aggressive Leukemia Assignment Report_6

Running head: MEDICAL6
2019). One of the most significant repair techniques is BER (Base Excision repair) required
for BRCA mutant cells which cause the ovarian cell death and breast cancers associated with
improper homologous recombination. Normal cells do not get affected.
Autophagy:
The sequential process involving cell death regulation and damaged cellular debris
recycling is initiated by external and cellular cures to maintain proper homeostasis and
metabolism. These conditions protect the cell against the oncogenic development which is
deregulated in a broad range of cancers (Zhang, Shang and Zhou 2015). When a cell is
observed to experience a nutrient deprivation or metabolic stress, the cell undergoes
catabolism to recycle the cellular organelles which are damaged and extract the proteins from
damaged of long-lived organelles.
Chloroquine
Chloroquine is an antimalarial agent, which is used in the treatment of erythematous,
and rheumatoid arthritis. Chloroquine acts by the inhibition of an autophagic flux during a
later stage to prevent the fusion of autophagosomes with lysosomes. This condition causes
the degradation of autolysosome (Verbaanderd et al. 2017).
Rapamycin
Also known as RAPA which is a member of the macrocyclic class of
immunosuppressive drugs that has been used as an immunosuppressive drug. The primary
target for rapamycin (mTOR) acts as an amino acid and ATP sensor involved in the balance
of nutrient availability. The majority of cancers show hyperactivity during the switching on
of mTOR by an oncogenic signaling pathway. Rapamycin inhibits the mTORC1 activity
which can also inhibit the actions of mTORC2 (Li, Kim and Blenis, 2014).
Aggressive Leukemia Assignment Report_7

Running head: MEDICAL7
Aims and Objectives
The main aim of this project is to check the effect of autophagy in STAG2 mutated cells with
a defect in DNA repair by using autophagy inducer rapamycin for the inhibition of mTOR
(mammalian TOR) in order to invoke a defect in DNA repair for the destruction of mutated
cells. Another autophagy inhibitor known as chloroquine is also used here which prevents the
fusion of lysosome and phagosome. Both these functions will be studies to provide a targeted
therapy required for the treatment of AML. This experiment will also aim to provide a sub
stratum for future research studies involving a more efficient treatment strategy.
The following three hypotheses will be tested:
1. STAG2 mutated cells will have their cellular deaths increased to a higher level than the
non-mutated cell line.
2. The cells, which are incubated with chloroquine, are expected to have an increased death
as compared to the cells treated with rapamycin.
3. The modulation of autophagy is expected to increase the drug sensitivity towards platinum.
Thus, cells which are incubated with a platinum-based chemotherapy drug (Cisplatin)
and autophagy modulators are expected to have the most amount of cell death.
Materials and Methods
Reagents: DMEM (Dulbecco’s modified eagle medium) with high concentration of glucose
(4500 mg/L), FBS (Fetal bovine serum), antibiotic- Streptomycin-Penicillin, PBS
(Dulbecco’s phosphate buffer saline), Trypsin-EDTA solution, Trypan Blue, DMSO
(Dimethyl sulfoxide), RAP (Drugs- autophagy inducer Rapamycin) [3150055-EMD
Millipore), CHL (Chloroquine diphosphate salt) [C6628-25G-25G –SIGMA-autophagy
Aggressive Leukemia Assignment Report_8

End of preview

Want to access all the pages? Upload your documents or become a member.